Abstract
Despite the remarkable emergence of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli sequence type 131 (ST131), the clinical features and outcomes of infections caused by ST131 remain poorly described. From 2011 to 2012, we collected ESBL-producing E. coli isolates from patients with bloodstream infections in 13 hospitals in Korea and compared clinical characteristics and outcomes between ST131 and non-ST131 clones. Of the 110 ESBL-producing isolates, the most common ST was ST131 (30.9%). Multivariate analysis showed that recent operation was the only variable associated with the ST131 clone; other comorbid conditions and clinical features were similar between ST131 and non-ST131 clones. CTX-M-14 and CTX-M-15 were the predominant types of ESBLs, and CTX-M-15 was significantly associated with ST131. The rate of nonsusceptibility to ciprofloxacin was higher in ST131 than in non-ST131 clones (94.1% vs. 75.0%). No significant differences in 30-day mortality rates were found between ST131 and non-ST131 clones. Multivariate analysis revealed that older age (odds ratio [OR]=5.39, 95% confidence interval [CI] 1.22-23.89; p=0.027), nosocomial infection (OR=4.81, 95% CI 1.15-20.15; p=0.032), and higher Pitt bacteremia scor...Continue Reading
References
Jun 1, 1992·Chest·R C BoneW J Sibbald
Sep 1, 1992·Antimicrobial Agents and Chemotherapy·K S Thomson, C C Sanders
Nov 19, 2002·Annals of Internal Medicine·N Deborah FriedmanDaniel J Sexton
Mar 31, 2005·FEMS Microbiology Letters·Jungmin KimDong-Taek Cho
Sep 13, 2007·The Journal of Antimicrobial Chemotherapy·Mitchell J Schwaber, Yehuda Carmeli
Dec 14, 2007·The Journal of Antimicrobial Chemotherapy·Marie-Hélène Nicolas-ChanoineJames R Johnson
Dec 25, 2007·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·G M RossoliniC Mugnaioli
Jan 18, 2008·Journal of Clinical Microbiology·Siu Ha LauMathew Upton
Feb 9, 2008·Emerging Infectious Diseases·Teresa M CoquePatrice Nordmann
Mar 13, 2008·The Journal of Antimicrobial Chemotherapy·Olivier ClermontGuillaume Arlet
May 17, 2008·Diagnostic Microbiology and Infectious Disease·Kwan Soo KoNam Yong Lee
Jun 10, 2009·Antimicrobial Agents and Chemotherapy·Stephen P HawserDavid L Paterson
Jan 12, 2010·International Journal of Antimicrobial Agents·Gisele Peirano, Johann D D Pitout
Nov 18, 2010·The Journal of Antimicrobial Chemotherapy·Benjamin A RogersDavid L Paterson
Nov 17, 2011·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Emilia TitelmanChristian G Giske
Nov 30, 2011·Antimicrobial Agents and Chemotherapy·Hsing-Chun ChungJiun-Ling Wang
Jul 4, 2012·BMC Infectious Diseases·Sun Hee ParkJin-Hong Yoo
Jul 17, 2012·Diagnostic Microbiology and Infectious Disease·Hitoshi KurodaMitsuo Kaku
Nov 2, 2012·Scandinavian Journal of Infectious Diseases·Cheol-In KangJong Kyun Lee
Mar 8, 2013·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Ritu BanerjeeJames R Johnson
Jul 16, 2013·Journal of Korean Medical Science·Cheol-In KangJae-Hoon Song
Sep 12, 2013·PloS One·Marie-Hélène Nicolas-ChanoineUNKNOWN Coli β study group
Citations
Jan 23, 2016·Journal of Medical Microbiology·Fusun CanOnder Ergonul
Apr 21, 2016·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Min Kyeong ChaJae-Hoon Song
Apr 21, 2016·The Korean Journal of Internal Medicine·So Yeon ParkJae-Hoon Song
Jun 30, 2018·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Ji Young ParkHoan Jong Lee
Sep 2, 2017·Korean journal of pediatrics·Ki Wook YunIn Seok Lim
Jan 10, 2019·Journal of Medical Microbiology·Xiao ChenYu Chen
Sep 15, 2019·Scientific Reports·Swaine L ChenDavid C Lye
Jul 28, 2020·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Masoumeh RasoulinasabMohammad Mehdi Aslani
Nov 9, 2017·Scientific Reports·Hyunsoo KimKyungwon Lee